FDA 审查了 linvoseltamab 的新申请，这是一种很有前途的多发性骨髓瘤治疗方法。 The FDA reviews a new application for linvoseltamab, a promising treatment for multiple myeloma.

林业发展局已同意审查重新提交的Linvoseltamab申请,这是对至少前四次治疗失败的多位骨髓瘤病人的一种可能的新治疗。 The FDA has accepted for review a resubmitted application for linvoseltamab, a potential new treatment for multiple myeloma patients who have failed at least four prior treatments. 该药物通过激活T细胞针对癌细胞,以前曾面临制造问题。 The drug, which targets cancer cells by activating T-cells, had previously faced manufacturing issues. 试验的最新数据显示,客观回应率为71%。 Updated data from trials show a 71% objective response rate. 美国食品药品监督管理局将在2025年7月10日之前作出决定. The FDA is set to decide by July 10, 2025.